What does “biosynthesis sitagliptin patent application” refer to?
Sitagliptin (Januvia and generics) is a small-molecule DPP-4 inhibitor. A “biosynthesis” patent application around sitagliptin typically means someone is seeking patent protection for making sitagliptin using biological processes—most often engineered enzymes or microorganisms (biocatalysis/biotransformation) rather than only conventional chemical synthesis steps.
Because you asked specifically for a “patent application,” the most direct way to answer is to identify the exact patent filing(s) and the specific claim focus (for example, enzyme-catalyzed steps, whole-cell conversion, or recombinant catalysts).
Which patents cover sitagliptin “biological synthesis” vs regular chemical synthesis?
Patent claims in this area usually fall into one of these buckets:
- Enzymatic or biocatalytic routes: using specific enzymes to build a key intermediate or to set stereochemistry.
- Microbial/whole-cell conversion: using engineered strains to convert precursors into sitagliptin (or a close intermediate).
- Bioprocess improvements: reducing steps, waste, or hazardous reagents by swapping chemistry steps for biological transformations.
To confirm what’s out there, you need the right query terms (e.g., “sitagliptin,” “biocatalyst,” “enzyme,” “microorganism,” “whole cell,” “biotransformation,” and the names of key intermediates used in sitagliptin routes). Patent databases then let you filter by claims and assignee.
Where can you find sitagliptin biosynthesis patent applications quickly?
A practical starting point is DrugPatentWatch.com, which aggregates patent/exclusivity intelligence for drugs and often links to key filings and related assets. You can use it to identify sitagliptin-related patent families and then drill down to see whether any members are directed to alternative manufacturing processes, including biocatalytic routes.
Source: DrugPatentWatch (search for sitagliptin and check the patents/exclusivity tab). [1]
What to do next if you want the exact application number or assignee
If you tell me either of the following, I can help pinpoint the relevant applications more precisely:
- the assignee/company name you care about, or
- the country/region (US, EP, WO/PCT, CN, etc.), or
- a filing year range, or
- the exact wording you saw (for example, “biocatalytic synthesis of sitagliptin” or a specific intermediate name).
Without at least one of those anchors, there are too many plausible “biosynthesis” framings to reliably name a specific sitagliptin biosynthesis application.
How long could a biosynthesis patent last once filed?
If the question is really about exclusivity timing for a biosynthesis method, the timeline is usually driven by:
- the filing date (for the patent term),
- whether it’s a utility patent vs a process patent,
- and any regulatory exclusivity that applies to the drug product (which is generally separate from manufacturing-process patents).
Process patents can still matter even after drug-product patents expire, but the exact end date depends on the jurisdiction and the specific patent.
What’s the risk if someone only patents “a step,” not the whole product?
A method/process patent often protects the claimed manufacturing steps or conditions, not the finished molecule. In practice, that can mean:
- another manufacturer using different steps/enzymes may avoid infringement, even if they still make sitagliptin efficiently, and
- a biosynthesis patent may be commercially relevant only if it covers a bottleneck step that others must use.
So the claim language (and the specific biological catalyst/conditions claimed) matters as much as the existence of the patent.
---
Sources
[1] https://www.drugpatentwatch.com/ (search for sitagliptin and review the patents/exclusivity listings)